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Introduction
With the advent of highly active antiretroviral therapy (HAART), 
the 25 million people living with HIV-1/AIDS in sub-Saharan 
Africa (SSA) now have the potential for a near-normal life 
expectancy1–3. Nonetheless, their wellbeing could be hampered 
by continuing HIV co-morbidities that adversely affect quality 
of life. HIV-associated neurocognitive disorder (HAND), at least 
in its mild form, is one of the commonest comorbidities. Briefly, 
HAND is a spectrum of neurological complications of HIV 
infection comprising asymptomatic neurocognitive impairment, 
mild neurocognitive disorder and HIV-associated dementia4. 
The diagnosis of HAND is based on the evaluation of key 
cognitive domains including executive functioning, episodic 
memory, motor skills, and speed of information processing, 
language, working memory, and sensory perception according 
to the Frascati criteria4. These criteria also consider the extent 
to which the cognitive impairment impacts the person’s 
performance on activities of daily living.
The prevalence of HAND is estimated to be high across regions, 
occurring in as many as 50% of all adults living with HIV, 
including those on HAART and with well-controlled viremia5–7. 
Nonetheless, its pattern has changed in the era of HAART8. 
Notably, the incidence of severe forms of HAND has reduced 
significantly, while the prevalence of moderate forms has 
increased5–7. The persistence of milder forms of HAND is 
hypothesized to be due to poor adherence to treatment, possible 
neurotoxicity, multiple co-morbidities, resistance to drugs, low 
educational achievement, irreversible CNS injury before ART 
initiation (the so-called legacy effect of untreated HIV), poor 
CNS penetration of some of the ARV drugs as well as chronic 
HIV brain infection9,10.
The magnitude of HAND among adults living with HIV, espe-
cially in SSA is largely unrecognized, partly because of the 
lack of expertise to recognize it and failure to routinely screen 
for it. Moreover, there is a paucity of well-designed epide-
miological studies describing the burden of the condition10,11. 
Understanding HAND is important because of its clinical and 
functional impact on the individual including the heightened 
risk of mortality12; poor treatment adherence13; poor quality 
of life14; increased risk-taking behaviors15 and disruptions to 
everyday functioning16.
Existing guidelines on the management of HAND almost exclu-
sively originate from high-income countries. These guidelines 
recommend that all people living with HIV be screened for 
HAND using standardized tools17. Thereafter, the frequency 
is contingent on whether HAND is already present or whether 
clinical data suggest increased risk for developing HAND. 
Additionally, worsening cognitive functioning may necessitate 
HAART modification when other causes have been excluded18. 
Other management approaches suggested in the literature include 
preventative and treatment strategies supporting the biopsy-
chosocial aspects of cognition, such as reducing alcohol and 
substance use, improving nutrition, treating comorbidities, pro-
moting social contact, reducing depression and stress levels, 
taking part in cognitively stimulating activities, applying cogni-
tive remediation therapies, and incorporating psychopharmaco-
logical interventions19,20. Nonetheless, there is limited empirical 
evidence documenting the appropriateness of the suggested 
HAND management approaches. There is a need for more 
research to build such evidence and after that, determine which 
packages of care could potentially be delivered by lay health 
care workers through task shifting in low-resource settings. Such 
an approach could prove effective in addressing some of the 
unique challenges facing the SSA region including inadequate 
staff with specialized skills, and the many competing healthcare 
needs.
Despite the potential benefits of early screening, few clinics 
in SSA screen for this condition in routine HIV care services. 
This is partly due to the lack of adequately standardized tools of 
neurocognitive functions21. Another barrier is the prevailing 
shortage of trained healthcare personnel with expertise to 
administer these tests.
Information on the most appropriate HAND screening tools 
in SSA is poorly addressed. In 2013, Zipursky and colleagues 
conducted the first systematic review of the literature with the 
aim of evaluating brief screening tools for HAND across the 
world21. Out of the 31 studies included in the past review, only 
5 were from SSA. Overall, the review demonstrated that the 
commonly utilized screening tools (HIV Dementia Scale (HDS) 
and the International HIV Dementia Scale (IHDS)) had poor 
(0.48) and moderate (0.62) pooled sensitivities, respectively. 
The authors further reported that none of the tools differentiated 
HAND adequately to suggest wider use. Moreover, substantial 
methodological flaws were reported in most of the studies. This 
included: the failure for the studies to use the “gold standard” 
neuropsychological battery as the reference test, failing to utilize 
more comprehensive reference tests, non-representativeness 
of the samples and the varied measurement of functional status. 
A recently published systematic review provided important 
information on the comprehensive neuropsychological 
assessment of NCI in people living with HIV in the SSA22.
Unlike the recently published review which focused on com-
prehensive neuropsychological assessment in SSA, our scop-
ing review focusses on the HAND screening tools that are being 
used in the region and document the extent of their validation. 
Precisely, we document the psychometric properties of these 
tools. Key constructs of reliability and validity are reviewed. 
Internal consistency (using Cronbach alpha correlation), 
test-retest reliability (often measured as correlation, with Pear-
son r), and inter-rater reliability (generally estimated by per-
cent agreement, kappa (for binary outcomes), or Kendall tau) 
            Amendments from Version 1
Aspects of the paper highlighting the clinical utility of HAND 
screening tools have been reduced and moved to a more 
discursive section in the discussion. We have also added a 
column in the main table, highlighting how HAND was assessed 
across the included studies to aid in the interpretation of the 
findings from the included studies. The listing of the statistical 
parameters needed for good quality studies have been moved 
from the introduction to the Methods section. More information on 
‘decent’ sensitivity, specificity, NPV and PPV has been provided 
in the discussion. We have also updated some of the references 
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will be examined to describe reliability. For validity, criterion- 
related validity (predictive, concurrence) and construct validity 
(convergent, discriminant)23 will be evaluated. The focus on SSA 
is important to provide context relevant information to guide both 
clinical and research practice in the region.
Methods
Search strategy
A comprehensive database search in Ovid Medline, PsycINFO 
and Web of Sciences was conducted for peer-reviewed articles 
published from January 1980 up to 31st August 2018. The search 
strategy was formulated by two reviewers (PNM and AA) and 
comprised of the following terms combined with Boolean 
operators: HIV-associated neurocognitive disorders OR cognitive 
impairment OR neurocognitive impairment OR neurological 
complications AND HIV OR HIV-1 OR HIV/AIDS AND adults 
OR youth OR older people AND Africa OR sub-Saharan Africa. 
Additionally, reference lists of retrieved studies were searched 
for potentially eligible studies that were not identified from the 
database search.
Inclusion and exclusion criteria
Studies are eligible if they met the following criteria: i) included 
participants who were HIV-infected and with documented 
HAND; ii) focussed on screening HAND; iii) were conducted 
in SSA; and iv) conducted among adults (mean or median age 
of at least 18 years). The exclusion criteria are: i) non-empirical 
studies; ii) studies using other methods for screening HAND 
apart from brief screening (taking more than 20 minutes); 
iii) studies published in other languages other than English; 
iv) studies not conducted among adults, and v) studies carried 
out outside SSA.
Data extraction
Data extraction was done by two independent reviewers 
(PNM and AA). The data was extracted to Microsoft Excel 
spreadsheets with the following details: first author, date of 
publication, country of origin, study design, patient character-
istics, tool administrators, type of screening tool used, reference 
neuropsychological tool used, and psychometric properties 
of the tool. For reliability, we extracted measures of internal 
consistency, test re-test and inter-rater reliability. For validity, we 
extracted construct, criterion, divergent or convergent validities 
whenever reported. Generally, a Cronbach alpha correlation close 
to 1 is considered good while a Pearson correlation ( r) ≥ 0.70 is 
considered good24,25
Data handling and synthesis
Data analysis involved collating and summarizing of results 
from individual studies. The synthesis of data extracted from 
the eligible studies is performed narratively. Frequencies and/or 
percentages are computed in Microsoft Excel program to 
summarize the findings on the frequency of the various tools 
reported in studies. Where applicable, ranges are used to 
compare the diagnostic accuracy and psychometric properties 
of the identified HAND screening tools in the final synthesis. 
Being a scoping review, risk of bias of individual studies was 




The search strategy yielded 479 studies (flow diagram given in 
Figure 1). Of the retrieved studies, 14 eligible articles were 
included in this review, and these were published between 2005 
and 2018. All the 14 included studies utilized a cross-sectional 
design. In total, nine (64.3%) of these studies were conducted in 
South Africa and the rest were conducted in Nigeria, Uganda and 
Kenya. The study samples ranged from 16 to 269 participants, as 
presented in Table 1.
Screening tools identified and their psychometric properties
IHDS. Of the reviewed studies, eight evaluated the validity 
and diagnostic accuracy of the International HIV dementia 
scale26–33 The International HIV dementia scale (IHDS) is a brief 
HAND screening measure made up of three items assessing 
motor speed, psychomotor speed and memory specifically 
developed for use in low- and middle-income countries30. It 
was initially evaluated in Uganda, where a cut-off of 10 was 
suggested, yielding a sensitivity of 80% and specificity of 
55%30. Subsequent validation studies of the IHDS (included 
in this review) have reported varied sensitivity and specificity 
(Table 1). Overall, sensitivity ranged from 45% to 100%28,29 and 
specificity ranged from 37% to 79%28,29. Data was unavailable on 
other key components of validity such as test-retest reliability and 
construct validity.
Kwasa and colleagues31 evaluated the utility of a modified version 
of the IHDS in Kenya, the HIV Dementia Diagnostic Test, (by 
adding neurological and functional status items). The modified 
tool exhibited moderate sensitivity and specificity of 63% 
and 67% respectively. Nonetheless, the inter-rater reliability 
was poor (K = 0.03–0.65), with the authors suggesting further 
training and formal evaluations for health care workers (HCW) 
to reliably administer the tool. Elsewhere in South Africa, 
Gouse and colleagues33 evaluated a version of the IHDS 
which had been modified by adding a brief self-report cogni-
tive tool. The modified IHDS tool was reportedly more effective 
(94% sensitivity, 63% specificity) in screening for severe forms 
of HAND than the original IHDS tool (74% sensitivity, 70% 
specificity).
HDS. HDS was originally developed in 1995 as a brief HAND 
screening tool34 with four scales designed to screen for cogni-
tive impairments in attention, motor speed, construction and 
working memory domains. Some of the subtests in the original 
version of HDS were deemed difficult for administration by 
non-neurologists and informally trained individuals, which led to 
the modified version, the IHDS in 200530. In the current review, 
the study by Olubunmi in Nigeria demonstrated good HDS 
sensitivity (97%) and specificity of 80% with a positive predic-
tive value (PPV) of 91% and a negative predictive value (NPV) 
of 93%35. Nonetheless, the HDS tool was insensitive to memory 
impairment in asymptomatic HIV-infected patients. Likewise, 
data was unavailable on other key components of validity, such 
as test-retest reliability and construct validity.
Montreal Cognitive Assessment (MoCA) test. The MoCA test 
is a brief screening tool originally developed in 1996 to screen 
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Figure 1. A flow diagram showing the article screening process of this review.
for mild cognitive impairment36. So far, only two studies in 
Africa (as identified in this review) have evaluated its utility in 
screening for HAND, both of which were in South Africa37,38. 
In the initial evaluation study38, the tool was able to discrimi-
nate neurocognitive performance between HIV-infected and 
non-infected individuals. However, it has problematic sections 
that need to be removed. Additionally, a ceiling effect was 
observed with some of the items making the authors conclude 
that the tool needs extensive cultural adaptation to make it 
suitable for South Africa’s linguistically, culturally, educationally, 
and economically diverse population. Reliability and construct 
validity were not explored in this initial evaluation. In the 
second evaluation study37, a moderate correlation (Pearson’s 
r = 0.36) was found between the tool and reference neuropsy-
chological battery. The tool demonstrated a sensitivity of 40%, 
a specificity of 72% and a diagnostic accuracy of 59%. With 
these results, the authors concluded that the MoCA test is not a 
reliable screening tool for cognitive impairment in HIV- 
infected patients in rural South Africa.
NeuroScreen. NeuroScreen is a computerized neuropsychologi-
cal screening test battery designed for a smartphone running on 
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the Android operating system. This measure is mobile-based, 
takes around 15–20 minutes to administer, and needs limited 
training. It was originally developed and tested in the United 
States of America42. The measure comprises 10 brief neuropsy-
chological tests assessing verbal learning, memory, processing 
speed, attention/concentration, executive functioning and motor 
functioning. In Africa, the NeuroScreen has only been evalu-
ated in South Africa39. In this review, the sensitivity of the 
NeuroScreen ranged between 81% to 93% and its specificity 
ranged from 71% to 81% when administered by lay health 
workers. Unfortunately, data was unavailable on other key 
aspects of validity such as test-retest reliability and construct 
validity.
CogState Brief Battery. This is a brief computerized neuropsy-
chological battery (taking around 15 minutes to administer) 
developed to screen and monitor cognitive impairment in 
patients including those living with HIV43,44. In SSA, the tool 
has been evaluated once in Uganda40. In this evaluation, the 
tool exhibited a sensitivity of 57% and a specificity of 74% at 
the optimal cut-off point. Data was also unavailable on other 
key components of validity such as test-retest reliability and 
construct validity.
Cognitive Linguistic Quick Test (CLQT). The sixth measure 
evaluated was the CLQT41. The measure was originally normed 
on 171 non-clinical and 38 clinical cases in the US as a quick 
screen for people to identify cognitive strengths and weak-
nesses in different at-risk populations. In the current review, it is 
difficult to make conclusions on the potential usefulness of 
this measure as a screening tool given its small sample size of 
16 participants and minimal psychometric evaluations,41.
Tool administrators
A total of eleven studies described the administrators of the 
HAND screening tools26,28,30–32,35,39–42. In nine of these 
studies, the administrators were trained research assistants who 
were either physicians, neuropsychology technicians, counsellors, 
nurses or clinical officers. There were two studies that 
included lay health workers in the screening for neurocogni-
tive impairment26,39. In one of them, the authors compared the 
effect of having trained research administrators versus lay 
administrators26. In the study by Kwasa and colleagues31, the 
agreement between healthcare workers and expert examiners 
was poor for many individual items of the tool (K = 0.03–0.6). 
Similarly, in another study by Breuer and colleagues, lay counsel-
lors tended not to miss symptoms, and detected symptoms more 
often than nurses for the IHDS26.
Methodological shortfalls of reviewed studies
Some of the reviewed studies had small sample sizes such as 
1641, 2032 and 3031. Additionally, only 9 studies28–33,37,39,40 utilized 
comprehensive neuropsychological battery to define HAND 
in the identified studies. Similarly, only seven studies28–31,33,35,37 
considered the functional status of their participants in 
categorizing neurocognitive impairment.
Discussion
We conducted the scoping review to identify the commonly used 
HAND screening tools in SSA and document their psychometric 
properties and diagnostic accuracy. The most frequently utilized 
HAND screening tool identified was the IHDS, observed in 
more than half of the included studies. The other tools reported 
were: MoCA, HDS, NeuroScreen, CogState cognitive battery, 
and the CLQT. Overall, our results show that most of the com-
monly utilized HAND screening tools in SSA are inadequately 
validated, with most of the studies only reporting specifi-
city and sensitivity while failing to document important vali-
dation constructs notably construct validity and reliability. 
Besides, close to two-thirds of the included studies originated 
from a single country (South Africa). This potentially limits the 
generalizability of the current evidence on screening tools for 
HAND to other settings in SSA. These results are similar to 
earlier reviews on HAND screening tools21,45.
Among the identified tools, IHDS had the most data on vali-
dation. However, its validation is suboptimal. Most studies 
reported only diagnostic accuracy26–32,35. There is hardly any data 
on its construct validity and reliability over time. Besides, the 
diagnostic accuracy reported is generally not within the expected 
range (sensitivity of ≥80% and specificity of ≥55%) with some 
studies having very low specificity (37%)29 and very low sensitivity 
(45%)28 for the IHDS. The huge variation in the diagnostic 
accuracy could partly be due to the non-standard definition of 
HAND in the different studies and possible sociodemographic 
and clinical heterogeneity of the included samples.
Generally, the limited data on construct validity and reliability 
as well as the variability of diagnostic accuracy of the reviewed 
studies do not imply that these measures are less robust and 
generalizable. This observation calls for more studies to cul-
turally adapt and validate these measures using well-designed 
studies to better understand their performance in the differ-
ent settings within the region. With more data, we would be 
able to accurately determine the psychometric properties of 
these tools. Typically, a cut-off value of 70% is recommended 
when selecting an optimal screening tool to yield a demand-
ing threshold for type I and II errors. Besides, screening tools 
with sensitivity close to a chance level (≤50%) are avoided. 
In principle, high NPV’s are regarded as important. Going 
by this guidance, many of the reported indexes of sensitivity, 
specificity, PPV and NPV would be inadequate. 
NeuroScreen, one of the most recent HAND screening tools is 
promising. Its initial evaluation in South Africa yielded good 
diagnostic accuracy when administered by lay healthcare work-
ers. The tool has the potential to address some of the unique 
challenges and gaps facing resource-limited settings in screening 
for HAND including difficulty in performing long test batteries, 
limited screening tools and a shortage of clinical staff. None-
theless, more research with larger samples should be under-
taken to validate the tool in several cultural settings in SSA 
to clarify its internal and external validity. Some of the issues 
raised during the initial evaluation need clarification in fur-
ther studies including the possibility of floor effects and prac-
tice effects. The MoCA, the other recent screening test, is 
gaining momentum in SSA. So far, its validation in SSA has 
yielded poor criterion validity, showing best test characteris-
tics when screening for severe forms of HAND, before it can be 
widely used, more studies are needed to validate it.
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It is worth noting that several methodological shortfalls were 
identified in the design and conduct of reviewed studies, which 
need to be considered by researchers in further validation stud-
ies. Some of the studies had small sample sizes and might have 
lacked the power to detect differences31,32,44. There was also a 
huge variation in the definition of HAND in the studies. Only 
nine out of the 14 studies reviewed utilized a reference 
neuropsychological battery to define HAND and few consid-
ered the functional consequences brought about by HAND. 
Additionally, hardly any study reported construct validity 
and reliability of the screening measure. It is imperative that 
these aspects of validation are conducted and reported to 
comprehensively assess the utility of the given tools. 
There is no doubt that the research on HAND screening 
is gaining momentum in the SSA region, as evidenced by 
an increasing number of studies on the subject.  Nonethe-
less, there is still a dearth of research on the clinical utility of 
HAND screening tools. Feasibility data would be critical in 
guiding the relevant stakeholders make informed deci-
sions regarding the screening of HAND. At the moment, the 
question as to whether all people living with HIV should 
be screened for HAND is an ongoing debate9. An expert 
committee drawn from 30 countries, the Mind Exchange Working 
Group, recommends the screening of HIV-infected people 
early in the disease and then every 6–24 months, regardless of 
symptoms or risk factors17. Another body, the British HIV 
Association, shares these sentiments by advocating for annual 
screening without giving details of the methods to be used or 
which populations to target46. Likewise, the European AIDS 
Clinical Society recommends that screening should be limited 
to patients showing symptoms of cognitive impairment47. Gen-
erally, universal screening interventions are rarely advocated, 
except when the screening strategy is very cheap, the screening 
measure has high accuracy, the consequences for being a false 
positive (such as distress, anxiety and healthcare costs) are 
minimal and the consequences of failing to diagnose are grave 
(that is, there is a highly effective and cost-effective intervention 
and a very poor outcome without the treatment). One impor-
tant screening strategy could be to identify known risk factors of 
HAND (from well-designed epidemiological studies and clinical 
practice) and use these to develop a risk score and only screen 
those with a higher risk score (this will increase the diagnostic 
accuracy of the screening tool). Another strategy could be to train 
health care workers to be more aware of the signs and cues of 
HAND and then conduct indicated screening only on patients with 
suggestive signs and symptoms. 
Our review has the following limitations. Firstly, we did not 
appraise the quality of the reviewed articles. Nonetheless, this 
is a primary limitation of scoping reviews; by not considering 
this, our study considered several articles that would have been 
excluded in a systematic review. Secondly, it is possible that 
we could have missed some articles not cited in the target 
databases during our literature search. Thirdly, the variation 
in the definition of HAND in some of the included studies may 
limit the comparison of the screening accuracy of identified tools 
across studies.
In conclusion, our review shows that there is limited evidence on 
the reliability and validity of commonly utilized HAND screen-
ing tools in SSA. A clear majority of the tools are inadequately 
validated and standardized with most of the reviewed studies 
only reporting diagnostic accuracy. Among the studies reporting 
diagnostic accuracy, there is substantial variability in sensitiv-
ity, specificity, PPV, and NPV. However, a few promising tools 
are available such as the NeuroScreen, but they lack norma-
tive data to suggest clinical usefulness. These findings empha-
size the need for well-designed studies to culturally adapt and 
validate HAND screening tools within the region. As this 
work continues, the next step would be to evaluate the clini-
cal utility of these tools. We acknowledge that this work 
would require an ongoing effort to correlate tool factors to 
theorized constructs of HIV disease. In addition to this, tool 
developers need to bear in mind the unique presentation of 
certain clients such as those with motor problems who may 
be naturally biased when taking HAND screening tests with 
greater emphasis on motor functions. The NeuroScreen 
presents good progress in this direction by assessing multi-
ple domains of executive functioning, such as working mem-
ory and attention. There is also an important need to understand 
how the current HAND screening tools perform amongst 
those aging with HIV. So far, none of the studies reviewed has 
explored this gap in research.
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“…...tool developers also need to bear in mind the unique presentation of certain clients
such as those with motor problems who may be naturally biased when taking HAND
screening tests with greater emphasis on motor functions. The NeuroScreen presents
good progress in this direction by assessing multiple domains of executive functioning
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good progress in this direction by assessing multiple domains of executive functioning
 such as working memory and attention.
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As suggested by the reviewer, the paragraph highlighting the clinical utility of HAND














We share the reviewer’s sentiments regarding the validity of the commonly used
screening tools in the region up to date. Our arguments don’t in any way disregard the
utility of the tools in question especially in the context of research. Our findings majorly
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utility of the tools in question especially in the context of research. Our findings majorly
emphasize the need for more focussed studies evaluating the construct validity and
reliability of these tools (which is inadequately addressed at the moment) while at the
same time appreciating the progress made so far. We have exercised due diligence in
highlighting this observation in the revised document. 
The suggested analyses (factor analysis or matrix analysis) would be difficult to do in the
given set of results. This partly because of the heterogeneity of the included studies.
Besides, we would require the original datasets of the studies which is beyond the scope






A column has been added in the main Table highlighting how HAND was assessed across
the included studies. Indeed, 65% (proportion of the studies which used
neuropsychological batteries in assessing HAND) is a reasonable figure. However, this
figure should not be viewed in isolation when evaluating how HAND was assessed. Some
of the studies (in the 65% figure) did not assess the functional status of the individuals
while some did not categorize HAND into the 3 categories recommended by the Frascati







This has been revised to reflect ‘clinically important changes’ and has been updated






We agree with the reviewer. To our knowledge, the screening of HAND in routine clinical







We agree with the reviewer. For clarity and consistency purposes, we have maintained the
term ‘mild’ and dropped ‘moderate’ whenever we have used the term to imply ‘less severe’
in to HAND. 
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This has been noted. We have included these factors as some of the possible causes of








We agree with the reviewer that this is a contentious issue. While there is some data
suggesting that certain factors e.g. low CD4 nadir, could be risk factors generally, there is
limited evidence    from well-designed epidemiological studies within the region







We agree with the reviewer, and this has been revised accordingly. We have inserted the
following statement. 
 
“……there is limited empirical evidence documenting the appropriateness of the
suggested HAND management approaches. There is a for more research to build such
evidence and thereafter    determine which packages of care could potentially be
delivered by lay health care workers through task shifting in low-resource settings. Such
an approach could prove effective in addressing some of the unique challenges facing the






We agree with the reviewer’s suggestion. We have moved the portion describing







We agree with the reviewer’s observation and as earlier stated, we have moved this
portion to a smaller discursive part towards the end of the paper. 
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The cited paper was excluded from the analysis because it did not aggregate the relevant
results (psychometric properties of the different tools) by geographic location; USA








From the results of this paper, we cannot make the conclusion the tools observed are ‘suboptimal’,
hence not fit for use. Our key observation and finding that virtually all studies reviewed hardly
reported construct validity and reliability of the tools they used. Besides, we also note that there is
variability in the reported indexes of sensitivity, specificity, PPV, NPV. We have included the
following statement (third paragraph of the discussion).
 
“Generally, the limited data on construct validity and reliability as well as the variability of
diagnostic accuracy of the reviewed studies do not imply that these measures are less
robust and . This observation calls for more studies to culturally adapt and validate these
measures using well-designed studies to better understand their performance in the
different settings within the region. With more data, we would be able to accurately
determine the psychometric properties of these tools and determine which ones are
consistently performing poorly and well. Normally, a cut-off value of 70% is recommended
when selecting an optimal screening tool to yield a demanding threshold for type I and II
errors. Besides, screening tools with sensitivity close to a chance level (≤50%) are
avoided. In principle, high NPV’s are regarded as important. Going by , many of the











This has been noted, and in response, we have reduced and shifted this portion to a less
discursive portion towards the end of the discussion. The small section on interventional
research when evaluating the clinical utility of HAND screening tools has been dropped as
the data do not directly speak to this. 
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